Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144841 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
A Phase 2 study of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT05144841 is a Phase 2 study of Relapsed or Refractory Diffuse Large B-Cell Lymphoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 140 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05144841, a Phase 2 study of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.
Conditions Studied
Interventions
- BIOLOGICAL Zilovertamab vedotin
Study Locations (20)
Ohio
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0217) - Cincinnati
- University Hospitals Cleveland Medical Center ( Site 0222) - Cleveland
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C - Columbus
California
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229) - Orange
- Innovative Clinical Research Institute ( Site 0202) - Whittier
Michigan
- University of Michigan ( Site 0200) - Ann Arbor
- Karmanos Cancer Institute ( Site 0216) - Detroit
District of Columbia
- Georgetown University Medical Center ( Site 0204) - Washington D.C.
Georgia
- Northside Hospital ( Site 0206) - Atlanta
Illinois
- University of Chicago Medical Center ( Site 0207) - Chicago
Indiana
- Franciscan St. Francis Health ( Site 0225) - Indianapolis
Maryland
- University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0211) - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2022-01-08 |
| Est. Completion | 2026-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05144841
The ClinicalTrials.gov registry entry for NCT05144841 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Diffuse Large B-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Zilovertamab vedotin is the first listed.
NCT05144841 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Ohio, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT05144841 about?
NCT05144841 is a clinical study titled "A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)". The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventi...
What is the current status of trial NCT05144841?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2022-01-08. Estimated completion is 2026-04-22.
What conditions does trial NCT05144841 study?
This clinical trial studies the following conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
What interventions are being tested in trial NCT05144841?
The interventions under investigation include: Zilovertamab vedotin (BIOLOGICAL).
Who is sponsoring clinical trial NCT05144841?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05144841 being conducted?
This trial has 20 study locations across California, District of Columbia, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.